MiRNAs associated with chemo-sensitivity in cell lines and in advanced bladder cancer

BMC Medical Genomics

Volumn 5, Issue , 2012, Pages

  Nordentoft, Iver ^a   Birkenkamp Demtroder, Karin ^a   Agerbæk, Mads ^a   Theodorescu, Dan ^b   Ostenfeld, Marie Stampe ^a   Hartmann, Arndt ^c   Borre, Michael ^a   Rntoft, Torben F ^a   Dyrskjøt, Lars ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FORMALDEHYDE; MICRORNA; MIR 138; MIR 27A; MIR 296 5P; MIR 642; MIR 886 3P; PARAFFIN; RNA; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CELL VIABILITY; CHEMOSENSITIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC CORRELATION; HUMAN; HUMAN CELL; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; RNA ANALYSIS; SURVIVAL TIME; TREATMENT OUTCOME; UPREGULATION;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CELL DEATH; CELL LINE, TUMOR; CISPLATIN; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; REFERENCE STANDARDS; REPRODUCIBILITY OF RESULTS; SURVIVAL ANALYSIS; TIME FACTORS; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 84865793020     PISSN: None     EISSN: 17558794     Source Type: Journal    
DOI: 10.1186/1755-8794-5-40     Document Type: Article

References (40)

1. Systemic therapy of advanced urothelial cancer. Vaishampayan U, Curr Treat Options Oncol 2009 10 256 266 10.1007/s11864-009-0101-9 19408129
2. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. Von Der MH, Sengelov L, Roberts JT, Ricci S, Dogliotti L, Oliver T, et al. J Clin Oncol 2005 23 4602 4608 10.1200/JCO.2005.07.757 16034041 (Pubitemid 46224062)
3. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. Von Der MH, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. J Clin Oncol 2000 18 3068 3077 11001674
4. MicroRNAs in Bladder Cancer. Williams MB, Liana A, MicroRNAs in Cancer Translational Research Springer Netherlands, Netherlands, Cho WCS, 2011 223 237
5. The miR-143/-145 cluster regulates plasminogen activator inhibitor-1 in bladder cancer. Villadsen SB, Bramsen JB, Ostenfeld MS, Wiklund ED, Fristrup N, Gao S, et al. Br J Cancer 2012 106 366 374 10.1038/bjc.2011.520 22108519
6. MicroRNA expression and function in cancer. Garzon R, Fabbri M, Cimmino A, Calin GA, Croce CM, Trends Mol Med 2006 12 580 587 10.1016/j.molmed.2006.10. 006 17071139 (Pubitemid 44780201)
7. MicroRNA expression profiles classify human cancers. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. Nature 2005 435 834 838 10.1038/nature03702 15944708 (Pubitemid 40839735)
8. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. Calin GA, Ferracin M, Cimmino A, Di LG, Shimizu M, Wojcik SE, et al. N Engl J Med 2005 353 1793 1801 10.1056/NEJMoa050995 16251535 (Pubitemid 41549891)
9. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Puerta-Gil P, Garcia-Baquero R, Jia AY, Ocana S, Alvarez-Mugica M, Alvarez-Ossorio JL, et al. Am J Pathol 2012 180 1808 1815 10.1016/j.ajpath.2012.01.034 22426337
10. Hedgehog pathway activation in human transitional cell carcinoma of the bladder. Pignot G, Vieillefond A, Vacher S, Zerbib M, Debre B, Lidereau R, et al. Br J Cancer 2012 106 1177 1186 10.1038/bjc.2012.55 22361633
11. Mammalian miRNA RISC recruits CAF1 and PABP to affect PABP-dependent deadenylation. Fabian MR, Mathonnet G, Sundermeier T, Mathys H, Zipprich JT, Svitkin YV, et al. Mol Cell 2009 35 868 880 10.1016/j.molcel.2009.08.004 19716330
12. Mechanisms of miRNA-mediated post-transcriptional regulation in animal cells. Chekulaeva M, Filipowicz W, Curr Opin Cell Biol 2009 21 452 460 10.1016/j.ceb.2009.04.009 19450959
13. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Proc Natl Acad Sci U S A 2004 101 2999 3004 10.1073/pnas.0307323101 14973191 (Pubitemid 38327724)
14. OncomiRs: the discovery and progress of microRNAs in cancers. Cho WC, Mol Cancer 2007 6 60 10.1186/1476-4598-6-60 17894887 (Pubitemid 350193892)
15. MicroRNA expression profiles for the NCI-60 cancer cell panel. Blower PE, Verducci JS, Lin S, Zhou J, Chung JH, Dai Z, et al. Mol Cancer Ther 2007 6 1483 1491 10.1158/1535-7163.MCT-07-0009 17483436 (Pubitemid 46954015)
16. MicroRNAs modulate the chemosensitivity of tumor cells. Blower PE, Chung JH, Verducci JS, Lin S, Park JK, Dai Z, et al. Mol Cancer Ther 2008 7 1 9 18187804
17. MicroRNAs and their target messenger RNAs associated with ovarian cancer response to chemotherapy. Boren T, Xiong Y, Hakam A, Wenham R, Apte S, Chan G, et al. Gynecol Oncol 2009 113 249 255 10.1016/j.ygyno.2009.01.014 19237188
18. Involvement of microRNA-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekhun VF, et al. Mol Cancer Ther 2008 7 2152 2159 10.1158/1535-7163.MCT-08-0021 18645025
19. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O, Int J Cancer 2010 127 1785 1794 10.1002/ijc.25191 20099276
20. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Yang N, Kaur S, Volinia S, Greshock J, Lassus H, Hasegawa K, et al. Cancer Res 2008 68 10307 10314 10.1158/0008-5472.CAN-08-1954 19074899
21. Predictive factors for response and prognostic factors for long-term survival in consecutive, single institution patients with locally advanced and/or metastatic transitional cell carcinoma following cisplatin-based chemotherapy. Jessen C, Agerbaek M, Von Der MH, Acta Oncol 2009 48 411 417 10.1080/02841860802325932 18798018
22. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, et al. Proc Natl Acad Sci U S A 2007 104 13086 13091 10.1073/pnas.0610292104 17666531 (Pubitemid 351737597)
23. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. J Natl Cancer Inst 2000 92 205 216 10.1093/jnci/92.3.205 10655437
24. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Andersen CL, Jensen JL, Orntoft TF, Cancer Res 2004 64 5245 5250 10.1158/0008-5472.CAN-04- 0496 15289330 (Pubitemid 39006544)
25. Down-regulation of miR-27a might inhibit proliferation and drug resistance of gastric cancer cells. Zhao X, Yang L, Wang Y, Hou R, J Exp Clin Cancer Res 2011 30 55 10.1186/1756-9966-30-55 21569481
26. MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Liu T, Tang H, Lang Y, Liu M, Li X, Cancer Lett 2009 273 233 242 10.1016/j.canlet.2008.08.003 18789835
27. MicroRNA-27a regulates basal transcription by targeting the p44 subunit of general transcription factor IIH. Portal MM, Proc Natl Acad Sci U S A 2011 108 8686 8691 10.1073/pnas.1014018108 21558443
28. Cooperative and individualistic functions of the microRNAs in the miR-23a 27a 24-2 cluster and its implication in human diseases. Chhabra R, Dubey R, Saini N, Mol Cancer 2010 9 232 10.1186/1476-4598-9-232 20815877
29. Upregulation of miR-23a-27a-24-2 cluster induces caspase-dependent and -independent apoptosis in human embryonic kidney cells. Chhabra R, Adlakha YK, Hariharan M, Scaria V, Saini N, PLoS One 2009 4 5848 10.1371/journal.pone. 0005848 19513126
30. miR-138 might reverse multidrug resistance of leukemia cells. Zhao X, Yang L, Hu J, Ruan J, Leuk Res 2010 34 1078 1082 10.1016/j.leukres.2009.10.002 19896708
31. MicroRNA-138 modulates DNA damage response by repressing histone H2AX expression. Wang Y, Huang JW, Li M, Cavenee WK, Mitchell PS, Zhou X, et al. Mol Cancer Res 2011 9 1100 1111 10.1158/1541-7786.MCR-11-0007 21693595
32. Alterations of microRNAs in Cisplatin-resistant Human Non-small Cell Lung Cancer Cells (A549/DDP). Wang Q, Zhong M, Liu W, Li J, Huang J, Zheng L, Exp Lung Res 2011 37 427 434 10.3109/01902148.2011.584263 21787234
33. The role of ABC transporters in clinical practice. Leonard GD, Fojo T, Bates SE, Oncologist 2003 8 411 424 10.1634/theoncologist.8-5-411 14530494 (Pubitemid 37238869)
34. Role of MicroRNA miR-27a and miR-451 in the regulation of MDR1/P-glycoprotein expression in human cancer cells. Zhu H, Wu H, Liu X, Evans BR, Medina DJ, Liu CG, et al. Biochem Pharmacol 2008 76 582 588 10.1016/j.bcp.2008.06.007 18619946
35. Down-regulation of miR-27a might reverse multidrug resistance of esophageal squamous cell carcinoma. Zhang H, Li M, Han Y, Hong L, Gong T, Sun L, et al. Dig Dis Sci 2010 55 2545 2551 10.1007/s10620-009-1051-6 19960259
36. miRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Lerner M, Lundgren J, Akhoondi S, Jahn A, Ng HF, Moqadam FA, et al. Cell Cycle 2011 10 2172 2183 10.4161/cc.10.13.16248 21597324
37. Precursor miR-886, a novel noncoding RNA repressed in cancer, associates with PKR and modulates its activity. Lee K, Kunkeaw N, Jeon SH, Lee I, Johnson BH, Kang GY, et al. RNA 2011 17 1076 1089 10.1261/rna.2701111 21518807
38. MicroRNA miR-886-5p inhibits apoptosis by down-regulating Bax expression in human cervical carcinoma cells. Li JH, Xiao X, Zhang YN, Wang YM, Feng LM, Wu YM, et al. Gynecol Oncol 2011 120 145 151 10.1016/j.ygyno.2010.09.009 20947150
39. Genomic profiling of microRNAs in bladder cancer: miR-129 is associated with poor outcome and promotes cell death in vitro. Dyrskjot L, Ostenfeld MS, Bramsen JB, Silahtaroglu AN, Lamy P, Ramanathan R, et al. Cancer Res 2009 69 4851 4860 10.1158/0008-5472.CAN-08-4043 19487295
40. MicroRNA expression signatures of bladder cancer revealed by deep sequencing. Han Y, Chen J, Zhao X, Liang C, Wang Y, Sun L, et al. PLoS One 2011 6 18286 10.1371/journal.pone.0018286 21464941